CLICK TO SHARE
Investors who take an interest in Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) should definitely note that insider John Scott recently paid US$0.90 per share to buy US$500k worth of the stock. That's a very decent purchase to our minds and it grew their holding by a solid 11%.
In fact, the recent purchase by insider John Scott was not their only acquisition of Navidea Biopharmaceuticals shares this year. They previously made an even bigger purchase of US$3.0m worth of shares at a price of US$0.75 per share. Even though the purchase was made at a significantly lower price than the recent price (US$1.05), we still think insider buying is a positive. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.
In the last twelve months Navidea Biopharmaceuticals insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
Navidea Biopharmaceuticals is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 36% of Navidea Biopharmaceuticals shares, worth about US$7.4m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
If you don't see any comments yet, congrats! You get first comment. Be nice and have fun.
CLICK TO SHARE